Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation - Insights from Castle HTX

9 April 2024 (13:15 - 13:27)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Christian Sohns

Heart and Diabetes Center NRW, Bad Oeynhausen (Germany)

4 More presentations in this session

Presentation thumbnail

Future LBS - Ground-breaking electroporation-based intervention for paroxysmal atrial fibrillation treatment: Rational and Design of the BEAT PAROX-AF randomized clinical trial

Professor P. Jais (Neuilly sur Seine, FR)

Presentation thumbnail

Future LBS - CAtheter-Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection Fraction

Associate Professor A. Parwani (Berlin, DE)

Presentation thumbnail

Future LBS - Initial Clinical Experience with the Volt PFA System: Acute Results of the VOLT CE Mark Feasibility Substudy

Professor P. Sanders (Adelaide, AU)

Presentation thumbnail

Future LBS - Safety, effectiveness and PVI durability of contact force-sensing dual energy focal ablation technology integrated with 3D mapping to treat paroxysmal atrial fibrillation: SmartfIRE study results

Doctor T. De Potter (Aalst, BE)

Access the full session

Session thumbnail

Late-Breaking Science today and tomorrow

The Event

Event poster

EHRA 2024

9 April 2024 13:15 CET

You may be interested in

Congress Presentation

Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial

Congress Presentation

CASTLE-HTx: Catheter Ablation versus Medical Therapy to Treat Atrial Fibrillation in End-stage Heart Failure

Congress Presentation

Patients with heart failure (REF and PEF) and atrial fibrillation should undergo pulmonary venous ablation - pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources